Key facts
- Tozaro’s last known valuation is $26.4M (Dec 2023).
- It has raised $31.3M; the latest was Secondary Transaction - Private ($210K) in Apr 2026.
- Notable investors include Innovate UK, Mercia Ventures, BGF (Financial Services), Wellcome Trust, Mercia Asset Management — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Tozaro
- ·The full record, as it builds
Funding rounds
No funding rounds for Tozaro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tozaro
Developer of a novel suite of reagents designed to support the development and manufacture of viral vectors in cell and gene therapy. The company's polymers and antibodies typically contain a single binding site for their target and can be fused to solid substrates, such as sensor surfaces, enabling hospitals to have ideal reagents for a wide range of applications, including point-of-care diagnostics and field-based testing.
- Sector
- Healthcare
- HQ
- Bedford, United Kingdom
- Founded
- 2015
- Employees
- 28
- Website
- tozaro.com/
- Ownership
- Privately Held (backing)
Tozaro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tozaro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tozaro in its N-PORT filings yet. We sweep new filings monthly.